The Animal Generic drug User Fee Act of 2008 (AGDUFA) (Title II of Public Law 110-316 signed by the President on August 14,2008), authorizes FDA to collect user fees for certain abbreviated applications for a generic new animal drug, om certain generic new animal drug products, and on certain sponsors of such abbreviated applications for generic new animal drugs and/or investigational submissions for generic new animal drugs. A generic animal drug application submitted by a person subject to application fees is considered incomplete and will not be accepted for filing by FDA until all fees owed by such person has been paid.
AGDUFA requires the submission of the user fees concurrently with applications. If the required fees are not submitted, the review of the application will not begin. The "User Fee Cover Sheet" provides the information to either initiate or defer the application review.
FDA is requesting emergency processing of this information collection request under the PRA of 1995 in order to comply with provisions of the Animal Drug User Fee Act of 2008 (AGDUFA. Under certain provisions of AGDUFA,the FDA is required to implemet a new user fee cover sheet, Form FDA 3728 in collection of user fees for all abbreviated applications for generic new animal drugs. The cover sheet in the AGDUFA User Fee System was scheduled to go into effect October 1, 2008, (assuming the enactment of an appropriation for these fees)
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.